不同剂量阿托伐他汀钙治疗脑梗死急性期的效果分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effect of different doses of Atorvastatin Calcium in the treatment of acute cerebral infarction(ACI).MethodsFrom June 2014 to July 2016,150 ACI patients admitted to our hospital were selected as research subjects.According to different dosage of atorvastatin calcium,they were evenly divided into three groups(10 mg,20 mg,and 40 mg)50 cases in each group.The medication was continued for 90 days.The indicators of low density lipoprotein cholesterol(LDL),total cholesterol(TC),triglyceride(TG),high sensitivity C-reactive protein(hs-CRP),intima-medial thickness(IMT),high density lipoprotein cholesterol(HDL),stroke scale(NIHSS),creatinine(Cr),uric acid(UA),blood urea nitrogen (BUN),and white blood cell(WBC)were compared before treatment,30 day,and 90 day after treatment.ResultsThe 30 day and 90 day treatments was compared with prior treatment,the levels of LDL,TC,and TG in three groups were all decreased significantly(P<0.05).However,after the treatment of 90 days,the LDL and TC levels in the 20 mg and 40 mg groups were significantly different than those in the 10 mg group(P<0.05).There was great difference in HDL level among three groups(P<0.05),while for TG level,it was not significant(P>0.05).After treatment for 30 and 90 days,the NIHSS scores were displayed statistical differences in comparison with that prior treatment among three groups(P<0.05).The score in 20mg and 40 mg groups was greatly different from that in 10mg group after 90 day treatment,but for the comparison of 20 mg and 40 mg groups,they were not obvious(P>0.05).After 30 day therapy,thehs-CRP level in 20 mg and 40 mg groups was displayed a statistical difference compared with that in 10mg group(P<0.05),but no statistical significance between 20 mg group and 40 mg group(P>0.05).On day 90,there was no significant difference in hs-CRP level among three groups (P>0.05).No significant change was detected in IMT,Cr,UA,BUN,or WBC before and after treatment among three groups(P>0.05).ConclusionAtorvastatin calcium in 20 mg can treat ACI in safe and effective,also reduces the hs-CRP level.

Key words： Atorvastatin Calcium Cerebralinfarction Therapeuticeffect High sensitivity C-reactive protein(hs-CRP)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Guo-hui
	LI Wen-dong
	QIAN Jian-ning

Cite this article:

CHENG Guo-hui,LI Wen-dong,QIAN Jian-ning. Effect analysis of Atorvastatin Calcium in different doses in the treatment of acute cerebral infarction[J]. 中国当代医药, 2017, 24(33): 88-90.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I33/88

[1]	郑侨克，熊强，罗浩，等.阿托伐他汀对急性缺血性脑卒中患者血浆溶血磷脂酸的影响[J].心血管康复医学杂志，2009，18（6）：579-581.
[2]	孙大宝，王真，苗军，等.阿托伐他汀对心源性脑栓塞患者T 淋巴细胞亚群的影响[J].脑与神经疾病杂志，2014，22（6）：446-448.
[3]	黄必武，郭韵诗，王子源.阿托伐他汀钙对急性脑梗死患者颈动脉硬化斑块及超敏C反应蛋白、血脂水平影响[J].中国当代医药，2016，23（36）：45-47.
[4]	刘伟，邵胜敏，李晟，等.阿托伐他汀钙对急性脑梗死患者血清 ET-1、PAO、H-FABP、VEGF、S100β、炎症因子及神经功能的影响[J].中国生化药物杂志，2015，35（3）：134-137.
[5]	刘坤，宫珍卿，王永久，等.阿托伐他汀钙对急性脑梗死患者血清C反应蛋白和肿瘤坏死因子-a的影响[J].中国医师进修杂志，2009，32（10）：15-18.
[6]	赵莲花，闫英群，郭再玉.阿托伐他汀钙对脑梗死患者血清hs-CRP、TNF-α水平变化疗效分析[J].中国生化药物杂志，2017，37（1）：179-181.
[7]	杨敏，唐明山.阿托伐他汀钙对脑梗死患者血脂、超敏C-反应蛋白和动脉粥样硬化的影响[J].四川医学，2013，34（5）：665-667.
[8]	林建武，周翼.阿托伐他汀钙对脑梗死急性期患者炎性因子表达及神经功能缺损的影响[J].中国生化药物杂志，2016，36（2）：97-99.
[9]	曾华.阿托伐他汀钙治疗脑梗死的效果及作用机制研究[J].临床医学工程，2015，22（9）：1167-1168.
[10]	张安兴.不同剂量阿托伐他汀钙预防颈动脉粥样硬化患者脑梗塞的作用[J].心血管康复医学杂志，2011，20（3）：256-257.
[11]	苏丹丹，肖波，毕方方.阿托伐他汀钙治疗急性脑梗死的有效剂量、最适剂量及安全性研究[J].河北医药，2016，38（16）：2450-2452.
[12]	杜文秀，李艳艳，史路遥，等.阿托伐他汀钙对急性脑梗死患者血浆S100B和高迁移率族蛋白1水平的影响[J].中华老年心脑血管病杂志，2016，18（9）：938-942.
[13]	张全新.大剂量阿托伐他汀治疗急性脑梗死患者的疗效观察[J].中华老年心脑血管病杂志，2014（8）：843-845.
[14]	李强，凌芳，聂德云，等.大剂量阿托伐他汀对急性脑梗死患者血清细胞因子及动脉粥样硬化斑块的影响[J].重庆医学，2012，41（16）：1598-1600.
[15]	禤彩霞，秦培英.不同剂量阿托伐他汀治疗急性脑梗死的疗效及对血脂和血清CRP的影响[J].延边医学，2015，10（9）：172-173.